Antisense oligonucleotides (AONs) are small molecules able to bind to the pre-mRNA and modulate splicing. The increasing amount of intronic mutations leading to pseudoexon insertion in genes underlying inherited retinal dystrophies (IRDs) has highlighted the potential of AONs as a therapeutic tool for these disorders. Here we describe how to design and test AON molecules in vitro in order to correct pre-mRNA splicing defects involved in IRDs.
CITATION STYLE
Garanto, A., & Collin, R. W. J. (2018). Design and in vitro use of antisense oligonucleotides to correct Pre-mRNA splicing defects in inherited retinal dystrophies. In Methods in Molecular Biology (Vol. 1715, pp. 61–78). Humana Press Inc. https://doi.org/10.1007/978-1-4939-7522-8_5
Mendeley helps you to discover research relevant for your work.